Table 1.
Main clinical characteristics of the patients
| Characteristics | Non‐methylated (%) (n = 145) | Methylated (%) (n = 107) | P‐value |
|---|---|---|---|
| Age (years) | NS | ||
| ≤60 | 70 (48) | 62 (58) | |
| >60 | 75 (52) | 45 (42) | |
| Sex | NS | ||
| Male | 80 (55) | 57 (53) | |
| Female | 65 (45) | 50 (47) | |
| WBC (×109/L) | NS | ||
| ≤10 | 66 (46) | 56 (52) | |
| >10 | 79 (54) | 51 (48) | |
| FAB classification | NS | ||
| M0 | 10 (7) | 6 (6) | |
| M1 | 35 (24) | 27 (25) | |
| M2 | 38 (26) | 28 (26) | |
| M4 | 26 (18) | 10 (9) | |
| M5 | 22 (15) | 15 (14) | |
| M6 | 9 (6) | 16 (15) | |
| M7 | 1 (1) | 1 (1) | |
| Unclassified | 4 (3) | 4 (4) | |
| Cytogenetic risk group | NS | ||
| Low | 5 (3) | 13 (12) | |
| Intermediate | 78 (54) | 63 (59) | |
| High | 29 (20) | 24 (22) | |
| Molecular alteration | NS | ||
| FLT3‐ITD | 20 (14) | 18 (17) | |
| NPM1 | 25 (17) | 12 (11) |
FLT3, Internal tandem duplication; NPM, nucleophosmin; NS, not significant; WBC, white blood cells.